Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Rochester, Minnesota 55905


Purpose:

OBJECTIVES: I. Assess the safety and effectiveness of budesonide in patients with primary sclerosing cholangitis or primary biliary cirrhosis experiencing a suboptimal response to ursodeoxycholic acid. II. Estimate the efficacy of this therapy in these patient groups as a means of evaluating the feasibility of a long-term randomized trial.


Study summary:

PROTOCOL OUTLINE: Patients receive budesonide by mouth 3 times daily for a minimum of 6 months. If liver biochemistries become normal, dosage is reduced to once daily. Treatment discontinues after 1 year.


Criteria:

PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Pathologically confirmed primary sclerosing cholangitis (PSC) meeting the following criteria: - Chronic cholestatic disease for at least 6 months - Liver biopsy within the past 6 months compatible with the diagnosis of PSC Intra and/or extrahepatic biliary duct obstruction, beading, or narrowing OR Pathologically confirmed primary biliary cirrhosis (PBC) that is experiencing suboptimal response to ursodeoxycholic acid and meeting the following criteria: - Chronic cholestatic liver disease for at least 6 months - Positive antimitochondrial antibody - No biliary obstruction by ultrasound, CT, or cholangiography - Prior liver biopsy compatible with diagnosis of PBC - Received ursodeoxycholic acid for at least 6 months --Prior/Concurrent Therapy-- Biologic therapy: - At least 3 months since prior D-penicillamine - No planned transplantation for at least 1 year Chemotherapy: - At least 3 months (6 months for PBC) since prior cyclosporin, colchicine, azathioprine, or methotrexate - At least 6 months since prior chlorambucil (PBC only) Endocrine therapy: At least 3 months (6 months for PBC) since prior corticosteroids Surgery: No prior intraductal stones or operations on the biliary tree except cholecystectomy (PSC only) Other: - At least 3 months since prior pentoxifylline, ursodeoxycholic acid, or nicotine (PSC only) - At least 6 months since prior chenodeoxycholic acid (PBC only) --Patient Characteristics-- Life expectancy: At least 3 years Hematopoietic: Not specified Hepatic: - Alkaline phosphatase at least 2 times upper limits of normal - No chronic hepatitis B infection - No hepatitis C infection - No autoimmune hepatitis - Bilirubin no greater than 4 mg/dL (PBC only) Cardiovascular: No severe cardiopulmonary disease Other: - No concurrent advanced malignancy - At least 3 months since prior inflammatory bowel disease requiring specific treatment except maintenance therapy (PSC only) - No anticipated need for transplantation within 1 year - Not pregnant - No liver disease of other etiology such as: Chronic alcoholic liver disease Hemochromatosis Wilson's disease Congenital biliary disease Cholangiocarcinoma No recurrent ascending cholangitis requiring hospitalization more than 2 times per year (PSC only) At least 1 year since prior active peptic ulcer No recurrent variceal bleeds No spontaneous encephalopathy No diuretic-resistant ascites


NCT ID:

NCT00004842


Primary Contact:

Study Chair
Keith D. Lindor
Mayo Clinic


Backup Contact:

N/A


Location Contact:

Rochester, Minnesota 55905
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 25, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.